Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

Table 3 Univariate and multivariate analysis with respect to progression free survival (PFS) in 30 advanced HER2-positive breast cancer

Parameters	Univariate			Multivariate
Parameters	Hazard ratio	95% CI	p value	Hazard ratio	95% CI	p value
Age at treatment
≤ 62 vs > 62	1.271	0.395–4.096	0.680
Degree of progress
Locally advanced vs visceral metastases	0.934	0.293–3.505	0.912
Stage
IIIC or IV vs recurrence	1.260	0.402–4.263	0.692
ER
Negative vs positive	1.581	0.494–5.063	0.431
PgR
Negative vs positive	0.925	0.246–2.948	0.898
Ki67
Negative vs positive	1.066	0.333–3.410	0.912
Treatment line
First vs other	1.449	0.452–4.643	0.522
CD8
Negative vs positive	0.162	0.009–0.837	0.027	0.333	0.017–2.349	0.292
FOXP3
Negative vs positive	0.513	0.137–1.632	0.263
CFR
Low/high	0.195	0.043–0.664	0.008	0.336	0.062–1.455	0.149
PD1
Negative vs positive	0.751	0.234–2.404	0.620
PD-L1
Negative vs positive	3.147	0.994–10.754	0.051	1.441	0.400–5.768	0.582
CD163
Negative vs positive	0.932	0.291–2.992	0.904
PTEN
Negative vs positive	0.814	0.240–2.556	0.725
LAG3
Negative vs positive	0.364	0.056–1.386	0.149

PFS, progression free survival; HER2, human epidermal growth factor receptor 2; CI, confidence intervals; ER, estrogen receptor; PgR, progesterone receptor; FOXP3, forkhead box protein 3; CFR, CD8/FOXP3 ratio; PD1, programmed death 1; PD-L1, programmed death ligand-1; PTEN, phosphatase and tensin homolog; LAG3, lymphocyte activation gene 3

ISSN: 1479-5876